Scott Rocklage’s Research Delivers Hope to Myotonic Dystrophy Sufferers

Early this year Expansion Therapeutics, with help from 5AM Ventures, Sanofi Ventures, Novartis Venture Fund, and Kleiner Perkins, began efforts to raise financing to fight genetic disorders, including myotonic dystrophy type I (DM1). Scott Rocklage, a Managing Partner of 5AM Ventures, was part of the science team of Matthew D. Disney, Ph.D. Their research is the basis for genetic disorders treatment development.

 

Myotonic dystrophy is a genetic disorder affecting muscles ability to relax; other symptoms may include intellectual disability and heart problems and currently, there is no cure. Expansion Therapeutics hopes to develop medications that would address disease RNA at molecule levels.

 

Dr. Scott M. Rockladge, Ph.D., received a Bachelor of Science degree in Chemistry from the University of California, Berkeley and Ph.D. in Chemistry from Massachusetts Institute of Technology. He is an inventor and co-inventor of over 30 patents and author of over 100 peer-reviewed publications. His experience in healthcare management lead to 3 FDA drug approvals: Omniscan™, Teslascan®, and Cubicin®.

 

Dr. Rocklage joined 5AM Ventures, a life science venture capital firm with $1 billion under management, in 2003 as a Venture Partner and currently serves as the Founding Partner. Since January 2018 he also serves as a Chairman of the Board of Directors of Expansion Therapeutics.

 

Dr. Rocklage has held several leadership positions at various healthcare companies including EPIRUS Biopharmaceuticals, Amersham Health, Cubist Pharmaceuticals, Novira Therapeutics, Milkana Therapeutics Inc., Ilypsa, Nycomed Salutar and several others. Currently, he is on the Boards of Rennovia, Kinestral, Cidara, Epirus and Pulmatrix.

 

Visit http://5amventures.com/team/scott-m-rocklage-phd/ to learn more.

Leave a Reply

Your email address will not be published. Required fields are marked *